Q + A
PT-141 FAQ
Twenty-two questions, answered from the cited record. No dosing recommendations.
How often can you take PT-141?
The approved label caps it at one 1.75 mg subcutaneous dose per 24 hours and no more than eight doses per month, as needed, for premenopausal women with HSDD [7]. The 52-week extension confirmed this as-needed pattern stayed tolerable, with nausea the chief limit [4]. This is the labelled limit, not a personal recommendation.
What are the side effects of PT-141?
In the 52-week extension (684 women), the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. The label adds a transient blood-pressure rise and, with frequent dosing, hyperpigmentation [7]. A program-wide synthesis confirmed nausea, flushing, and headache as the leading events [8].
Why does PT-141 cause nausea?
Nausea is the most common adverse event (~40% over long-term use) and traces to central melanocortin (MC4R) activation, the same brain pathway driving the desire effect [4][1]. It was the principal tolerability issue and a notable driver of discontinuation in the trials [4]. Injection timing has been studied as a mitigation.
Does PT-141 raise blood pressure?
Yes — transiently. The prescribing information documents a temporary rise in blood pressure after each dose and contraindicates use in uncontrolled hypertension or known cardiovascular disease [7]. The short half-life (~2.7 h) means the effect is brief rather than sustained [7]. It is a labelled warning, not a theoretical one.
Does PT-141 cause skin darkening or hyperpigmentation?
It can, with repeated frequent dosing. Hyperpigmentation of the face, gums, and breasts has been reported and is attributed to activation of the MC1R receptor on pigment cells — a melanocortin receptor distinct from the MC4R desire target [7]. The risk rises with dosing frequency.
Is PT-141 safe?
In the 52-week extension, no new safety signals emerged and the profile stayed stable [4]. The main issues are common nausea, a transient blood-pressure rise (contraindicated in uncontrolled hypertension), and frequency-dependent hyperpigmentation [4][7]. LiverTox notes rare clinically apparent liver injury [10]. "Research chemical" supply is unregulated and uncharacterized [12].
What is PT-141?
PT-141 is bremelanotide, a synthetic cyclic heptapeptide and analogue of alpha-MSH that activates central melanocortin receptors (MC3R/MC4R) [1]. It is FDA-approved as an injection for premenopausal women with HSDD [7]. Its mechanism is central — it acts on the brain's desire circuitry, not on blood flow [1].
What is PT-141 peptide?
The PT-141 peptide is a seven-amino-acid ring (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, MW 1025.2 Da) modelled on the natural melanocortin alpha-MSH [1]. The cyclic lactam structure makes it more stable than a linear peptide. It is an agonist at MC3R/MC4R in the central nervous system [1].
What does the PT-141 peptide do?
It switches on central melanocortin MC4R circuits tied to sexual desire [1]. In rats and primates, systemic dosing produced erections and activated hypothalamic neurons; in women with HSDD it raised desire and lowered desire-related distress [1][3]. A 2022 fMRI study showed it altered how the brain processed erotic stimuli [5].
What is PT-141 used for?
Its one approved use is treating acquired, generalized HSDD in premenopausal women [7]. Uses in men, postmenopausal women, or for performance are off-label or investigational and not the basis for approval [7]. The studied benefit is increased sexual desire and reduced desire-related distress [3].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development code; bremelanotide is the international nonproprietary name for the same melanocortin receptor agonist [1]. The approved injection is bremelanotide [7]. Material sold as "PT-141 research chemical" is the same molecule by name but outside the approval framework and quality-uncontrolled [12].
What is bremelanotide?
Bremelanotide is the INN for PT-141 — a synthetic alpha-MSH analogue and MC3R/MC4R agonist approved in 2019 (NDA 210557) as an injection for premenopausal women with HSDD [7][1]. It acts centrally on sexual-desire circuitry rather than on vascular blood flow [1].
How does PT-141 work?
It activates central melanocortin MC4R (and MC3R) receptors in hypothalamic circuits such as the medial preoptic area, engaging dopamine pathways tied to sexual desire [1]. In animals it activated hypothalamic neurons (raised c-Fos); in humans, fMRI showed altered central processing of erotic cues [1][5]. The mechanism is in the brain, not the blood vessels [7].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with secondary action at MC3R, both concentrated in the central nervous system [1]. A separate receptor, MC1R on pigment cells, accounts for the hyperpigmentation seen with frequent dosing [7]. MC4R also sits in appetite circuits, the basis for caloric-intake effects at high-frequency dosing [7].
Does PT-141 work through the brain or through blood flow?
Through the brain. Systemic dosing activated hypothalamic neurons in animals, and a human fMRI study showed it altered central processing of erotic stimuli [1][5]. It is not a PDE-5 inhibitor and does not act on vascular smooth muscle — the key contrast with blood-flow drugs [7].
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that switches on melanocortin receptors (MC1R–MC5R), the family that responds to natural peptides like alpha-MSH [1]. PT-141 is one — it activates the central MC3R/MC4R subtypes involved in sexual desire [1]. MC4R also influences appetite; MC1R influences skin pigment [7].
Does PT-141 increase testosterone?
No. PT-141 does not act via the HPG (hypothalamic-pituitary-gonadal) axis and does not directly raise testosterone — a common misconception [7]. Its effect is central melanocortin signalling on desire circuitry, not a hormonal one [1]. It is also not a PDE-5 inhibitor [7].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow. PT-141 acts centrally, activating brain melanocortin MC4R circuits that govern sexual desire and arousal [1][7]. One targets plumbing; the other targets wanting. The mechanisms are distinct, and so are the side-effect profiles.
What is the PT-141 dosage?
The approved label specifies 1.75 mg subcutaneous as-needed for premenopausal women with HSDD, capped at one dose per 24 hours and eight per month [7]. Terminal half-life is ~2.7 h (range 1.9–4.0 h) [7]. This is the labelled dose, stated as the label states it — not a recommendation for any individual.
How much PT-141 should I take?
This site recommends no dose for anyone. The only approved dose is the labelled 1.75 mg subcutaneous as-needed for premenopausal women with HSDD, with the dosing caps and the blood-pressure contraindication noted on the label [7]. Dosing decisions belong with a licensed clinician, not a website.
How much PT-141 to inject?
The approved injection dose on the label is 1.75 mg subcutaneous, as needed, for the HSDD indication in premenopausal women — no more than one dose in 24 hours [7]. That is a labelled value, not guidance. Phase 2 dose-finding had evaluated 0.75, 1.25, and 1.75 mg before 1.75 mg advanced [7].
What is the PT-141 dosage for women?
For the approved indication, the label dose is 1.75 mg subcutaneous as-needed [7]; Phase 2 had tested 0.75, 1.25, and 1.75 mg in women first [7]. The preclinical rationale came from female rats, where the peptide selectively increased appetitive sexual behaviour [2]. Stated as studied — not a recommendation.